Biosynthesis of silver nanoparticles from Hyphaene thebaica fruits and their in vitro pharmacognostic potential
Abstract
Hyphaene thebaica fruit extracts were applied as a low cost bio-reductant as well as capping agents for the biosynthesis of anisotropic silver nanoparticles (AgNPs). The AgNPs (4.5 nm–70 nm) revealed interesting morphologies and were characterized through diverse techniques. Characteristic Surface Plasmon Resonance (SPR) was observed at 411 nm which was stable in different physiochemical buffers suggesting excellent stability of silver. Zeta potential was recorded as −0.346 mV. X-ray Diffraction (XRD) pattern revealed formation of crystalline silver in pure phase also complemented by EDS (Energy Dispersive x-ray Spectroscopy). Fourier Transformed Infrared Spectroscopy (FTIR) indicated involvement of different phytochemicals as reducing and stabilizing agents. High Resolution-Transmission Electron Microscopy revealed interesting morphologies like spherical, rods, cubes etc. The multifunctional nanomedicinal application of AgNPs were assessed using different in vitro assays like antibacterial, antifungal, enzyme inhibition, antioxidant etc. AgNPs effectively inhibited bacterial strains of Bacillus subtilis, Pseudomonas aeruginosa and fungal strains of Aspergillus flavus and Mucor sp. Excellent DPPH radical scavenging (86%) is reported at 400 μg ml−1, while good total antioxidant capacity is observed. A dose dependant cytotoxicity is reported while blood compatibility at low doses is observed. AgNPs also revealed inhibition of protein kinase enzyme.
How strong is the evidence?
Evidence Hub reads this as a experimental / empirical study, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.